Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M49.2Revenue $M1.3Net Margin (%)-1,094.7Z-Score0.8
Enterprise Value $M41.2EPS $-1.3Operating Margin %-1,074.0F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-1,093.5Higher ROA y-yN
Price/Book3.210-y EBITDA Growth Rate %-38.9Quick Ratio7.4Cash flow > EarningsY
Price/Sales35.45-y EBITDA Growth Rate %-59.9Current Ratio7.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-67.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-74.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M11.8ROI % (ttm)-70.6Gross Margin Increase y-yY

Gurus Latest Trades with ROSG

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

ROSG is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ROSG: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about ROSG :

    Quarterly/Annual Reports about ROSG:

      News about ROSG:

      Articles On GuruFocus.com
      Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance Nov 18 2014 
      Rosetta Genomics Reports Second Quarter Financial Results, Provides Business Update Sep 08 2009 
      Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd. Jan 08 2009 
      Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 09 2008 

      More From Other Websites
      Nasdaq stocks posting largest volume increases Apr 14 2015
      Rosetta Genomics Completes Acquisition of PersonalizeDx Apr 14 2015
      Rosetta Genomics Completes Acquisition of PersonalizeDx Apr 14 2015
      Rosetta Genomics to Acquire PersonalizeDx Apr 09 2015
      Rosetta Genomics to Acquire PersonalizeDx Apr 09 2015
      Rosetta Genomics Receives Key U.S. Patent Allowance for its Novel Kidney Cancer Test Mar 26 2015
      Rosetta Genomics Receives Key U.S. Patent Allowance for its Novel Kidney Cancer Test Mar 26 2015
      Rosetta Genomics to Launch Next-Generation Sequencing Panel from Admera Health Mar 25 2015
      Rosetta Genomics to Launch Next-Generation Sequencing Panel from Admera Health Mar 25 2015
      ROSETTA GENOMICS LTD. Financials Mar 24 2015
      Rosetta Genomics Reports 2014 Financial Results Mar 16 2015
      Rosetta Genomics Reports 2014 Financial Results Mar 16 2015
      Q4 2014 Rosetta Genomics Ltd Earnings Release - 10:00 am ET Mar 16 2015
      Rosetta Genomics to Host Business Update and 2014 Year End Financials Conference Call on March 17,... Mar 10 2015
      Rosetta Genomics to Host Business Update and 2014 Year End Financials Conference Call on March 17,... Mar 10 2015
      Rosetta Genomics to Present at the 27th Annual ROTH Conference Mar 04 2015
      Rosetta Genomics to Present at the 27th Annual ROTH Conference Mar 04 2015
      Rosetta Genomics’ Novel and Differentiated Thyroid Cancer Assay Moves to Advanced Stages of... Feb 26 2015
      Rosetta Genomics’ Novel and Differentiated Thyroid Cancer Assay Moves to Advanced Stages of... Feb 26 2015
      ROSG: Broad Patent Allowances Assure Sustainable Growth Feb 20 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK